Acurx Pharmaceuticals, Inc. Reports Third Quarter 2024 Results and Provides Business Update
Acurx Pharmaceuticals, Inc. (ACXP)
Company Research
Source: PR Newswire
STATEN ISLAND, N.Y., Nov. 13, 2024 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("we" or "Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today certain financial and operational results for the third quarter ended September 30, 2024.Highlights of the third quarter ended September 30, 2024, or in some cases shortly thereafter, include:In July 2024, results from the ibezapolstat (IBZ) Phase 2 clinical trial in patients with C. difficile Infection (CDI) were presented at the 17th Biennial Congress of the Anaerobe Society of the Americas by Taryn A. Eubank, PharmD, BCIDP, Research Assistant Professor, University of Houston College of Pharmacy delivered an oral presentation entitled: "Clinical Efficacy of Ibezapolstat in CDI: Results from Phase 2 trials."Also in July 2024, and very timely given our late-stage development progress, the USPTO (United States Patent and T
Show less
Read more
Impact Snapshot
Event Time:
ACXP
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ACXP alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ACXP alerts
High impacting Acurx Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
ACXP
News
- Acurx Pharmaceuticals, Inc. Announces Closing of $1.1 Million Registered Direct OfferingPR Newswire
- Acurx Pharmaceuticals, Inc. Announces $1.1 Million Registered Direct Offering [Yahoo! Finance]Yahoo! Finance
- Acurx Pharmaceuticals, Inc. Announces $1.1 Million Registered Direct OfferingPR Newswire
- Acurx Announces Publication of Nonclinical In Vivo Data Differentiating Ibezapolstat's Gut Microbiome Effects from Other Anti-CDI Antibiotics [Yahoo! Finance]Yahoo! Finance
- Acurx Announces Publication of Nonclinical In Vivo Data Differentiating Ibezapolstat's Gut Microbiome Effects from Other Anti-CDI Antibiotics [Yahoo! Finance]Yahoo! Finance
ACXP
Earnings
- 11/13/24 - Beat
ACXP
Analyst Actions
- 1/10/25 - HC Wainwright
ACXP
Sec Filings
- 3/10/25 - Form 8-K
- 3/10/25 - Form 424B5
- 2/26/25 - Form 8-K
- ACXP's page on the SEC website